Practice Fusion users will have to pay for software after Allscripts acquisition

After its $100 million acquisition by Allscripts, Practice Fusion has been telling physicians its free software business model will be coming to an end this summer, according to CNBC.

The free model had helped Practice Fusion gained a foothold among solo practices, owning 15 percent of that market share in 2015. Instead of continuing to make money through pharmaceutical ads on its platform, customers have begun being notified they’ll soon have to pay $100 per physician per month.

In a statement to CNBC, Practice Fusion said a change is on the way in March, though it didn’t confirm the switch to a subscription-based model.

The change could open the door for challengers like CareCloud to eat away at Practice Fusion’s market share among independent practices which can’t afford more expensive electronic health record software.

“Maintaining the customer base could be a challenge because they're charging for something that was once free,” said CareCloud CEO Ken Comee. “It might encourage doctors to evaluate their options.”

Read more at the link below:

""
John Gregory, Senior Writer

John joined TriMed in 2016, focusing on healthcare policy and regulation. After graduating from Columbia College Chicago, he worked at FM News Chicago and Rivet News Radio, and worked on the state government and politics beat for the Illinois Radio Network. Outside of work, you may find him adding to his never-ending graphic novel collection.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.